PA Zucali
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
Mark M, Rusakiewicz S, Früh M, Hayoz S, Grosso F, Pless M, Zucali P, Ceresoli G, Maconi A, Schneider M, Froesch P, Tarussio D, Benedetti F, Dagher J, Kandalaft L, von Moos R, Tissot-Renaud S, Schmid S, Metaxas Y. Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. ESMO Open 2022; 7:100446.
12.04.2022Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
12.04.2022ESMO Open 2022; 7:100446
Mark M, Rusakiewicz S, Früh M, Hayoz S, Grosso F, Pless M, Zucali PA, Ceresoli G L, Maconi A, Schneider M, Froesch P, Tarussio D, Benedetti F, Dagher J, Kandalaft L, von Moos R, Tissot-Renaud S, Schmid S, Metaxas Y
2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
Gillessen Sommer S, Fléchon A, Stoiber F, Kollmansberger C, Germa-Lluch J, Horwich A, Zucali P, Gross-Goupil M, Bachner M, Oechsle K. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2012; 23:59-64.
13.12.20122-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
13.12.2012Ann Oncol 2012; 23:59-64
Gillessen Sommer Silke, Fléchon A, Stoiber F, Kollmansberger C, Germa-Lluch JR, Horwich A, Zucali PA, Gross-Goupil M, Bachner M, Oechsle K